

**MINUTES OF TECHNICAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/24-11 (TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS FOR
DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 11th February 2025

Venue: BMSICL Conference Hall.

The **Technical Evaluation Committee Meeting** for **Tender No. BMSIC/DRUGS/24-11** was held on **11th February 2025** under the Chairmanship of Dr. Pramod Kumar Singh, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Shailesh Kumar, Additional Secretary, Department of Health, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
5. Sh. Sunil Kumar Singh, GM (Logistics), BMSICL.
6. Sh. Navneet Kumar, DGM (Drugs), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/24-11.
2. Tender floated date- 23/10/2024.
3. Last date of submission of online bids- 26/11/2024.

3. The Tender has been floated on e-proc2 Portal for 07 (Seven) Drugs.

4. Total 10 (Ten) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

Sl No.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s Agio Pharmaceuticals Ltd.	Ok	Received	Ok
2	M/s Eskag Pharma Pvt. Ltd.	Ok	Received	Ok
3	M/s Kras Pharmaceuticals Pvt. Ltd.	Ok	EMD Exempted as per Bihar Industrial Investment Policy, 2016 as amended in 2020.	Ok
4	M/s Ornate Labs Pvt. Ltd.	Ok	EMD Exempted as per Bihar Industrial Investment Policy, 2016 as amended in 2020.	Ok
5	M/s Relief Biotech Pvt. Ltd.	Ok	Received	Ok
6	M/s Sam Kem	Ok	Received	Ok
7	M/s Super Formulations Pvt. Ltd.	Ok	Received	Ok
8	M/s Unicare India Ltd.	Ok	Received	Ok
9	M/s Zenith Drugs Ltd.	Ok	Received	Ok
10	M/s Navkar Lifesciences	Ok	Not Received	Not Ok

5. The firm M/s Navkar Lifesciences has not submitted the hard copy of Earnest Money Deposit (EMD). Accordingly, it was unanimously decided by TEC in its meeting dated 28/11/2024 to recommend for considering only those above nine (09) mentioned bidders (Sl. No. 01 to 09) who have successfully submitted their bids online as well as EMD in hard copy.

6. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Cloxacillin 250 mg Powder for Injection Vial	No Bidder Participated	0
2	Dicyclomine HCl 10 mg Tablet	M/s Kras Pharmaceuticals Pvt. Ltd.	5
		M/s Ornate Labs Pvt. Ltd.	
		M/s Relief Biotech Pvt. Ltd.	
		M/s Super Formulations Pvt. Ltd.	
		M/s Unicure India Ltd.	
3	Ethambutol 800 mg Tablet	No Bidder Participated	0
4	Gentamicin Injection 10mg/ml Injection 2 ml Vial	No Bidder Participated	0
5	Itraconazole Capsule 200 mg Capsule	M/s Kras Pharmaceuticals Pvt. Ltd.	4
		M/s Relief Biotech Pvt. Ltd.	
		M/s Unicure India Ltd.	
		M/s Zenith Drugs Ltd.	
6	Mupirocin 2% Ointment 5 gm tube	M/s Agio Pharmaceuticals Ltd.	6
		M/s Eskag Pharma Pvt. Ltd.	
		M/s Sam Kem	
		M/s Super Formulations Pvt. Ltd.	
		M/s Unicure India Ltd.	
7	Olopatadine HCl Ophthalmic Solution 0.1% w/v Eye Drop 5 ml Bottle	M/s Zenith Drugs Ltd.	0
		No Bidder Participated	

7. The summary of Bid received status was as follows:

1. No Bids received for **04** Drugs.
2. Multiple Bids received for **03** Drugs.

8. It was therefore unanimously decided by TEC in its meeting dated 28/11/2024 to recommend for Re-tender of Drugs at NIT S.N.- 1, 3, 4 & 7 (**04 Drugs**) due to no bid condition and to evaluate the bids for Drug at NIT S.N.- 2, 5 & 6 (**03 Drugs**) for which multiple bids have been received.

9. The Preliminary Evaluation of technical bids from the aforementioned bidding firms was conducted by the assigned team, including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the BMSICL website, and claims/objections were invited online vide notice no. 8786 dated 24/12/2024 on e-proc2.

10. After evaluating the clarifications received from the bidders in response to the notice and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings for each firm were recorded by TEC in its meeting dated 21/01/2025 with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	NIT S.N.	Name of the Drug	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	2	Dicyclomine HCl 10 mg Tablet	M/s Kras Pharmaceuticals Pvt. Ltd.	Qualified	Ok
			M/s Ornate Labs Pvt. Ltd.	Qualified	Ok
			M/s Relief Biotech Pvt. Ltd.	Qualified	Ok
			M/s Super Formulations Pvt. Ltd.	Qualified	Ok
			M/s Unicare India Ltd.	Qualified	Ok
2	5	Itraconazole Capsule 200 mg Capsule	M/s Kras Pharmaceuticals Pvt. Ltd.	Qualified	Ok
			M/s Relief Biotech Pvt. Ltd.	Qualified	Ok
			M/s Unicare India Ltd.	Qualified	Ok
			M/s Zenith Drugs Ltd.	Disqualified	Valid Pollution Control Clearance Certificate as per Clause 3(f) not submitted
3	6	Mupirocin 2% Ointment 5 gm tube	M/s Agio Pharmaceuticals Ltd.	Qualified	Ok
			M/s Eskag Pharma Pvt. Ltd.	Qualified	Ok
			M/s Sam Kem	Qualified	Ok
			M/s Super Formulations Pvt. Ltd.	Qualified	Ok
			M/s Unicare India Ltd.	Qualified	Ok
			M/s Zenith Drugs Ltd.	Disqualified	Valid Pollution Control Clearance Certificate as per Clause 3(f) not submitted

11. According to the comparative chart above, a total of eight (08) bidders namely, M/s Agio Pharmaceuticals Ltd., M/s Eskag Pharma Pvt. Ltd., M/s Kras Pharmaceuticals Pvt. Ltd., M/s Ornate Labs Pvt. Ltd., M/s Relief Biotech Pvt. Ltd., M/s Sam Kem, M/s Super Formulations Pvt. Ltd. & M/s Unicare India Ltd. were found technically qualified not withstanding their product wise qualification status as mentioned above.

12. One firm i.e., M/s Zenith Drugs Ltd. was found technically disqualified.

13. The manufacturing unit of the seven (07) technically qualified firms namely, M/s Agio Pharmaceuticals Ltd., M/s Kras Pharmaceuticals Pvt. Ltd., M/s Ornate Labs Pvt. Ltd., M/s Relief Biotech Pvt. Ltd., M/s Sam Kem, M/s Super Formulations Pvt. Ltd. & M/s Unicare India Ltd. were inspected during last three years and/or having valid rate contact with BMSICL.

14. It was therefore unanimously decided by TEC in its meeting dated 21/01/2025 to recommend for factory inspection of remaining one (01) technically qualified firm i.e., M/s Eskag Pharma Pvt. Ltd.

15. The visiting team of Drug Inspectors was not allowed to inspect the firm by M/s Eskag Pharma Pvt. Ltd., who cited that an audit would be conducted for a few days by a team from the Philippines. Hence, it was unanimously decided not considering the firm M/s Eskag Pharma Pvt. Ltd. for further process.

16. It was therefore unanimously decided to recommend for opening of the financial bids of rest seven (07) technically qualified firms on e -proc2 Portal.

17. The meeting thus concluded with a vote of thanks.

Sd/-
(Navneet Kumar)
DGM (Drugs), BMSICL, Patna.

Sd/-
(Sunil Kumar Singh)
GM (Logistics), BMSICL.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C
Procurement, SHSB.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Shailesh Kumar)
Additional Secretary, Department of Health, GoB.

Sd/-
(Dr. Pramod Kumar Singh)
Director in Chief, Health Dept.,
Govt. of Bihar.